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Background
Allergic rhinitis (AR) has been estimated to affect
approximately 20–25% of Canadians. [1] Management of
AR encompasses allergen avoidance, use of symptomatic
medications, and allergen immunotherapy for patients
unresponsive to other pharmacotherapy. [2,3] This study
was conducted to characterize patients receiving subcuta-
neous immunotherapy (SCIT) and the SCIT administra-
tion process in Canada and the United States; Canadian
results are presented.
Methods
A multi-center, prospective, observational study was con-
ducted at 5 allergy clinics in Quebec and Ontario and 1
primary care clinic in Quebec from March-September
2012. Patients ≥6 years who were scheduled for SCIT on
study days were invited to participate in the study. Patients
enrolled in a clinical trial, receiving sublingual immu-
notherapy or allergic only to insect venom, latex, food, or
drugs were excluded. Site and patient-specific information
were captured via direct observation, questionnaires, and
medical chart review. Costs were estimated from time and
supply observation and query.
Results
A total of 294 patients were enrolled with a mean age of
44 years (4% <18 years and 9% ≥65 years). Of these, 59%
were female, 81% Caucasian, 57% employed full-time and
30% reported household income ≥$100,000. Concomitant
allergy medications were reported by 66% of patients;
25% used asthma medications. Two-thirds of patients
reported initiating SCIT because they desired a cure
“once and for all” for their allergies. Primary symptoms
at initiation of SCIT were nasal congestion (62%), rhinor-
rhea (59%), sneezing (35%) and itchy eyes (32%). Chart
data indicated that patients received treatment for several
different antigens (mean: 4; SD: 3); those most commonly
noted were ragweed (82%), house dust mites (55%), grass
(48%) and tree (48%). Sites reported a SCIT build-up
phase requiring one injection/week over 12-52 weeks.
The SCIT maintenance phase was reported as one injec-
tion/month over 4-5 years. Site-specific means (SDs) for
total patient time in the clinic for SCIT ranged from 32
(11) to 49 (10) minutes, including a 30-minute required
post-injection observation at all but one site. Average
patient travel time to the office for SCIT was 20 (SD: 14)
minutes. Mean time missed from work in the previous
week was 0.7 hours. The direct costs of an injection
ranged from $14 to $41 by site, with extract preparation
or acquisition and administrative tasks the largest
components.
Conclusions
Patients initiated SCIT to permanently resolve allergy
symptoms. SCIT requires a long-term commitment,
resulting in considerable direct and indirect costs.
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